+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
ID05861895

Phase 1 Study Evaluating Safety and Early Effects of HF158K1 in Adults With Advanced Solid Tumors Expressing HER-2

Led by HighField Biopharmaceuticals Corporation · Updated on 2026-06-26

84

Participants Needed

2

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying HF158K1, an investigational liposome form of doxorubicin hydrochloride combined with a HER2-targeting antibody fragment, in adults with advanced solid tumors that express HER-2. The study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of HF158K1 in patients whose tumors have either high or low HER-2 expression and who have not responded to or cannot tolerate standard treatments. This multi-regional, open-label study includes dose-escalation, dose-bridging, and dose-expansion phases to evaluate different patient populations and ethnic groups. Participants receive HF158K1 through intravenous infusion on the first day of each 3-week treatment cycle. Three dose groups are studied 1.4 g, 2.2 g, and 2.9 g lipid doses. Each infusion lasts about 90 minutes and is diluted in glucose or saline to a total volume of 250 ml. The study includes a dose-escalation phase to find the maximum tolerated dose, a bridging phase to compare safety and pharmacokinetics across ethnicities, and a dose-expansion phase to further evaluate safety and early effects in selected tumor types. During the study, participants undergo regular assessments including blood and urine tests, vital signs, and heart function evaluations at baseline, each treatment cycle start, and at the end of treatment with follow-up up to one year. Researchers monitor adverse events, dose-limiting toxicities, and various laboratory parameters to evaluate the drugs safety and effects. Tumor response and disease control rates are also measured for up to 51 weeks to understand preliminary efficacy. The study is sponsored by HighField Biopharmaceuticals Corporation and spans from screening through treatment and follow-up periods.

CONDITIONS

Brief Title

HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here